This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Health technology
Low dose subcutaneous recombinant human erythropoietin (75-95 units/kg/week).
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis.
Study population
End stage renal disease patients.
Setting
The study was carried out in the United Kingdom.
Dates to which data relate
It seems that price related to 1989.
Source of effectiveness data
Single study.
Study sample
There is no evidence that the study sample is representative of the clinical study question. The number of patients overall was 60, with 60 in each of the intervention and control groups. No patients refused to participate.
Study design
Single centre, retrospective before-after study, with no blinding. The duration of follow-up of treatment cohort was 1 year post-, 1 year pre-intervention. Drop out were unknown.
Analysis of effectiveness
Analysis was based on intention to treat. Primary outcome was the maintenance of haemoglobin concentration. At analysis groups were not shown or adjusted to be comparable in age, sex or prognostic features.
